TARSUS PHARMACEUTICALS, INC. Number of Reportable Segments
TARSUS PHARMACEUTICALS, INC. (TARS) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment, a 0.00% change year-over-year.
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2025-03-31 was 1.00 segment, a 0.00% change year-over-year.
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2024-03-31 was 1.00 segment, a 0.00% change year-over-year.
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for the quarter ending 2023-03-31 was 1.00 segment, a 0.00% change year-over-year.
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for fiscal 2024 was 1.00 segment, a 0.00% change from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for fiscal 2023 was 1.00 segment, a 0.00% change from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. number of reportable segments for fiscal 2022 was 1.00 segment, a 0.00% change from fiscal 2021.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-23 | |||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | 1.00 segment 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-02-25 | |||
| 2024-09-30 | 1.00 segment 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | 1.00 segment 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 1.00 segment 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 1.00 segment 10-K · filed 2024-02-27 | |||
| 2023-09-30 | 1.00 segment 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 1.00 segment 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 1.00 segment 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | 1.00 segment 10-K · filed 2023-03-17 | |||
| 2022-09-30 | 1.00 segment 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | 1.00 segment 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 1.00 segment 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | 1.00 segment 10-K · filed 2022-03-14 | |||
| 2021-09-30 | 1.00 segment 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 1.00 segment 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | 1.00 segment 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | 1.00 segment 10-K · filed 2021-03-31 | |||
| 2020-09-30 | 1.00 segment 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |